Have you watched our audience size grow rapidly over the past few years and wondered how you could engage with it?
BioInformant’s audience includes:
- Online readers of BioInformant.com – The website attracts nearly one million unique viewers per year (65,000 – 75,000 per month).
- 7,200+ Push Notification Subscribers – These subscribers receive slide-in notifications about new content on the site.
- 45,000+ Email Subscribers
- 21,200+ Twitter followers
- 4,300+ Facebook followers
- 28,000+ LinkedIn followers [Cade Hildreth, Founder]
Additionally, we are a Top Contribute in LinkedIn Groups where we can reach another 150,000+ readers on your behalf.
We also control hundreds of stem cell terms on Google (1st page results). If you partner with us, we are experts in Search Engine Optimization (SEO) will get your content ranked by Google to drive continuous daily traffic.
Options to reach our audience include:
-
Press Release Publication
While we have spent many years and over a million dollars to go our audience, you can reach it for only $297.
For this small investment, we will publish your press release to BioInformant.com to reach nearly a million readers per year from across the stem cell industry.
We will also share your news announcement across all of BioInformant’s audience channels, including to our large Social Media followings on LinkedIn, Twitter, and Facebook.
Additionally, we will distribute it to our Email Subscribers (45,000+) and Push Notification (7,200+) Subscribers, as well as SEO optimize it to rank high in Google Search to drive continuous organic traffic every day.
Because this is a both a quick and cost effective way to access BioInformant’s large and targeted audience, we currently do Press Release Publication for nearly all of the leading companies within the stem cell sector.
In short, you get access to BioInformant’s full audience (across all channels) that has taken us many years and over a million dollars to acquire and you will have created an “evergreen” asset for you company that will permanently live on our site.
Learn how you can get know across the stem cell industry by clicking here. If you have further questions, email us at [email protected]
-
Inclusion in Email Newsletter – Reaches 45,000+ Subscribers
Inclusion in our weekly Email Newsletter is only $497 for a one-time inclusion or $797 for two inclusions (40% off the second inclusion) or $997 for three inclusions (an even greater discount).
This includes a one-time placement of either a Banner Ad (600 x 150 px) or a Native Inclusion (which includes Title, Link, and 3-4 Sentence Short Description) about your company/product/event.
Reach out to us at [email protected] to see examples or get your content included in our next Email Newsletter to 45,000+ stem cell industry subscribers.
-
Native Content
This is another popular option. Sponsored Article to get your content published to our site, distributed across all of our audience channels and SEO optimized to rank high in Google Search.
Sponsored Interviews can also be published and distributed across all of BioInformant’s audience channels.
Importantly, you get substantial credibility when a third-party releases news about your company.
Please contact our Content Team at [email protected] check availability, request pricing, and schedule your content release date.
-
Website Ads
Because we want our site to remain focused on high-quality content, BioInformant offers extremely limited advertising to leaders within the stem cell and cell therapy fields.
You can currently see square (300 x 300 px) ads in our left sidebar, as well as select inline ads within our articles.
We are extremely rare as a publisher in that we do not rotate our ads, so if you are able to place one on our site, it will reach every single visitor (65,000 – 75,000 per month / ~840,000 per year).
To inquire about ad availability, please email [email protected].
For additional questions about any of these options, we would love to hear from you at [email protected]. We look forward to introducing your company to our audience.